|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
42% (15 of 21 specimens), but there was only 40% positivity (8 of 20 specimens) for hepatitis B virus envelope antigen whereas 6 of 17 patients (35.29%) showed the presence of antibodies against hepatitis B virus envelope protein.
|
10738214 |
2000 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus type 1 (HIV-1) entry is triggered by the interaction of the gp120 envelope glycoprotein with a cellular chemokine receptor, either CCR5 or CXCR4.
|
11356952 |
2001 |
|
Herpes Simplex Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Herpes simplex virus (HSV) entry requires the interaction between the envelope glycoprotein D (gD) and a cellular receptor such as nectin-1 (also named herpesvirus entry mediator C [HveC]) or HveA/HVEM.
|
11836420 |
2002 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.
|
12615904 |
2003 |
|
Hepatitis A
|
0.040 |
Biomarker
|
disease |
BEFREE |
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.
|
12615904 |
2003 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human immunodeficiency virus type 1 envelope glycoprotein 120 induces cyclooxygenase-2 expression in neuroblastoma cells through a nuclear factor-kappaB and activating protein-1 mediated mechanism.
|
16001969 |
2005 |
|
Influenza
|
0.100 |
Biomarker
|
disease |
BEFREE |
Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors.
|
16397505 |
2006 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.
|
18343477 |
2008 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) is subject to both neutralizing antibody (NAb) and CD8 T-cell (cytotoxic T-lymphocyte [CTL]) immune pressure.
|
19515763 |
2009 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human immunodeficiency virus 1 (HIV-1) encephalopathy is thought to result in part from the toxicity of HIV-1 envelope glycoprotein gp120 for neurons.
|
19525894 |
2009 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus type 1 (HIV-1) entry is mediated by the interaction between a variably glycosylated envelope glycoprotein (gp120) and host-cell receptors.
|
20439465 |
2010 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus (HSV) entry into cells is triggered by the binding of envelope glycoprotein D (gD) to a specific receptor, such as nectin-1 or herpesvirus entry mediator (HVEM), resulting in activation of the fusion effectors gB and gH and virus penetration.
|
20861246 |
2010 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus entry into cells requires the binding of envelope glycoprotein D (gD) to an entry receptor.
|
21382632 |
2011 |
|
Severe Acute Respiratory Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis.
|
22028656 |
2011 |
|
Influenza
|
0.100 |
Biomarker
|
disease |
BEFREE |
Influenza virus hemagglutinin (HA) is the viral envelope protein that mediates viral attachment to host cells and elicits membrane fusion.
|
22072785 |
2012 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.
|
22855498 |
2012 |
|
Infectious Mononucleosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Infectious mononucleosis and B-cell transformation in response to infection with Epstein-Barr virus (EBV) is dependent upon binding of the EBV envelope glycoprotein gp350 to CD21 on B-cells.
|
23665339 |
2013 |
|
Dengue Fever
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dengue-1 envelope protein domain III produced in Pichia pastoris: potential use for serological diagnosis.
|
23993978 |
2013 |
|
West Nile viral infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
West Nile virus genome with glycosylated envelope protein and deletion of alpha helices 1, 2, and 4 in the capsid protein is noninfectious and efficiently secretes subviral particles.
|
24049184 |
2013 |
|
Influenza
|
0.100 |
Biomarker
|
disease |
BEFREE |
Influenza vaccines must be frequently reformulated to account for antigenic changes in the viral envelope protein, hemagglutinin (HA).
|
26739054 |
2016 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C Virus Subtype 3a Envelope Protein 1 Binding with Human Leukocyte Antigen Class I Types of Pakistani Population: Candidate Epitopes for Synthetic Peptide Vaccine.
|
26742442 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus (HCV) envelope glycoprotein complex is composed of E1 and E2 subunits.
|
28179528 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus (HIV) envelope glycoprotein (glycoprotein 120, gp120) can induce chronic neuropathic pain by directly stimulating primary sensory afferent neurons.
|
28827078 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein 120 has been shown to activate microglia, causing release of inflammatory and toxic factors.
|
28832643 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus type 1 (HIV-1) assembles as immature particles, which require the proteolytic cleavage of structural polyprotein Gag and the clustering of envelope glycoprotein Env for infectivity.
|
28916807 |
2017 |